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Loss of SPARC-mediated VEGFR-1 
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antiangiogenic activity of VEGF-A
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VEGF-A	promotes	angiogenesis	in	many	tissues.	Here	we	report	that	choroidal	neovascularization	(CNV)	incit-
ed	by	injury	was	increased	by	excess	VEGF-A	before	injury	but	was	suppressed	by	VEGF-A	after	injury.	This	
unorthodox	antiangiogenic	effect	was	mediated	via	VEGFR-1	activation	and	VEGFR-2	deactivation,	the	latter	via	
Src	homology	domain	2–containing	(SH2-containing)	tyrosine	phosphatase-1	(SHP-1).	The	VEGFR-1–specific	
ligand	placental	growth	factor-1	(PlGF-1),	but	not	VEGF-E,	which	selectively	binds	VEGFR-2,	mimicked	these	
responses.	Excess	VEGF-A	increased	CNV	before	injury	because	VEGFR-1	activation	was	silenced	by	secreted	
protein,	acidic	and	rich	in	cysteine	(SPARC).	The	transient	decline	of	SPARC	after	injury	revealed	a	temporal	
window	in	which	VEGF-A	signaling	was	routed	principally	through	VEGFR-1.	These	observations	indicate	that	
therapeutic	design	of	VEGF-A	inhibition	should	include	consideration	of	the	level	and	activity	of	SPARC.
Introduction
VEGF-A, which signals through the receptor tyrosine kinases 
VEGFR-1 and VEGFR-2, plays a dominant role in physiologic and 
pathologic angiogenesis, with VEGFR-2 implicated as its princi-
pal proangiogenic transducer. The function of VEGFR-1 is more 
nebulous. In vitro studies in porcine aortic (1) or human umbilical 
vein endothelial cells (2, 3) demonstrate that VEGFR-1 repressed 
VEGFR-2–mediated cell proliferation through active signaling. 
Deletion of Vegfr1 in mice results in embryonic lethality due to 
endothelial overcrowding and disorganized vasculature (4). How-
ever, vascular development is grossly unaffected in mice with a 
deletion of the VEGFR-1 kinase domain (Veg fr1 tk–/–) (5), which 
suggests that VEGFR-1 subserves a negative role in embryogenesis 
by acting as a trap that modulates endogenous VEGF-A levels. In 
pathologic angiogenesis, however, conflicting data about VEGFR-1 
function have emerged from studies demonstrating that it both 
amplifies (6, 7) and antagonizes (8) neovascularization. VEGFR-1 
signaling therefore appears to be both cell/tissue specific and con-
text/stage dependent.
Choroidal neovascularization (CNV) is the principal cause 
of blindness in patients with age-related macular degeneration 
(AMD), a condition responsible for vision loss in 25–30 million 
people worldwide in total (9). VEGF-A is present in CNV mem-
branes surgically excised from patients with AMD (10), and phar-
macological inhibition of VEGF-A decreases experimental laser-
induced CNV (11). These data are the bases for current clinical 
trials of anti–VEGF-A therapy in patients with AMD.
However, the precise role of VEGF-A in CNV remains unclear. 
Whereas subretinal injection of viral vectors encoding VEGF-A leads 
to retinal pigmented epithelium (RPE) overexpression of VEGF-A 
and subsequent CNV (12), increased production of VEGF-A direct-
ed by RPE-specific promoters, such as RPE65 or VMD2, does not 
produce CNV (13, 14). However, enhancement of VEGF-A coupled 
with subretinal injection of null viral vector induced CNV (14), sug-
gesting that increased VEGF-A alone is insufficient to induce CNV 
without concomitant mechanical trauma or immune deviation. A 
clinical trial of an anti–VEGF-A aptamer (pegaptanib) in CNV dem-
onstrated an inverse dose response in visual outcome (15). Further, 
although the lowest dose decreased the rate of vision loss, it did not 
prevent an increase in CNV lesion size.
It is now appreciated that activities of VEGF-A and other cytokines 
are influenced by the interaction of cells with the ECM. Matricel-
lular proteins regulate cell-ECM communication and thereby can 
influence many remodeling events, including angiogenesis (16). We 
focused on the matricellular protein SPARC (secreted protein, acid-
ic and rich in cysteine) because it has been reported to decrease the 
stimulatory activity of VEGF-A on endothelial cell proliferation, in 
part by its abrogation of VEGFR-1 phosphorylation (17).
Results
VEGF-A inhibits CNV via VEGFR-1. We tested the effect of injecting 
VEGF-A into the vitreous cavity of mice after laser injury. This 
injury fractures Bruch membrane, the ECM between the RPE and 
choroid, the highly vascular tissue beneath the RPE, and triggers 
proliferation of choroidal endothelial cells that subsequently 
migrate through these fractures, resulting in CNV (18, 19). Intra-
vitreous injection of VEGF-A (0.02–0.95 pmol), either immedi-
ately following or 1 day after laser injury, decreased the volume 
of CNV in a dose-dependent fashion at both 1 (Figure 1, A and B) 
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and 2 weeks (data not shown) after laser injury. CNV volume in 
eyes injected with vehicle (PBS) alone did not differ significantly 
from that in the uninjected fellow eyes; further, CNV volume in 
eyes treated with VEGF-A did not depend on whether the fellow 
eye was uninjected or treated with PBS or VEGF-A (Figure 1C).
To test whether endogenous VEGF-A would induce similar 
effects, we injected CoCl2, which increases VEGF-A expression. 
Intravitreous injection of CoCl2 (0.77 nmol) 1 day after laser injury 
decreased the volume of CNV compared with PBS or no injection; 
this inhibition was abrogated by neutralizing anti–VEGF-A anti-
body but not by isotype control IgG (Figure 1D). We confirmed 
the functional specificity of this anti–VEGF-A antibody by dem-
onstrating that it modestly inhibited CNV, in comparison with 
control IgG, consistent with previous reports of VEGF-A blockade 
(11). Although CoCl2 can induce pleiotropic effects in cells, reversal 
of the antiangiogenic effect by specific neutralization of VEGF-A 
confirms its involvement in suppressing CNV. Because hypoxia 
has been speculated to be involved in CNV (reviewed in ref. 20), 
the effects of CoCl2 might be pathophysiologically relevant.
Because VEGF-A binds both VEGFR-1 and VEGFR-2, we tested 
the effects of placental growth factor-1 (PlGF-1), a VEGFR-1–spe-
cific ligand (21), and VEGF-E, a VEGFR-2–specific ligand (22). 
Intravitreous injection of PlGF-1 (0.03–43.1 pmol) resulted in simi-
lar dose-dependent suppressive effects on CNV, whereas VEGF-E 
(0.11–1.14 pmol) did not (Figure 1B). Inhibition of CNV by VEGF-A 
or CoCl2 was abolished by neutralizing antibody against VEGFR-1 
(40 pmol; IC50 = 13.3–53.3 nM) but not by anti–VEGFR-2 (1.7 pmol; 
IC50 = 0.7–2 nM) or by isotype control antibody (40 pmol) (Figure 
2A). At the doses used, intravitreous injection of anti–VEGFR-2 
antibody modestly reduced CNV, confirming a prior report (23); 
however, intravitreous injection of anti–VEGFR-1 antibody did 
not reduce CNV, a result different from a prior report of systemic 
VEGFR-1 blockade (24) (discussed below). The modest increase in 
CNV induced by VEGF-E was blocked by anti–VEGFR-2 antibody 
but not anti–VEGFR-1 or isotype control antibody, confirming the 
specificity and effectiveness of these doses (Figure 2A). That CNV 
reduction induced by PlGF-1 was not enhanced by coadministra-
tion of VEGF-E suggests that cooperation between VEGFR-1 and 
VEGFR-2 is not required for antiangiogenic activity (Figure 1B). 
Although VEGF-E alone increased CNV volume, it was unable to 
overcome the antiangiogenic effect of PlGF-1, demonstrating the 
dominance of VEGFR-1 over VEGFR-2 in this context.
VEGFR-1 blockade augmented the increase in CNV induced by 
VEGF-E (Figure 2A); in the setting of exogenously triggered selec-
tive VEGFR-2 signaling, endogenous VEGFR-1 activation there-
fore appears to function as a negative regulator of angiogenesis. 
Administration of VEGF-A and CoCl2 increased CNV in Vegfr-1 
tk–/– mice, results opposite of those seen in wild-type mice and sup-
portive of a negative regulatory function for VEGFR-1 during this 
angiogenic response (Figure 2B). Collectively, these data demon-
strate that the suppressive effects of VEGF-A occur through active 
VEGFR-1 signaling and not by its functioning as a decoy receptor 
sequestering ligand from VEGFR-2.
Endogenous VEGF-A induces a zone of angiogenic inhibition. These 
data may be relevant to clinical observations. Specifically, ophthal-
mologists have noted that there is often a single area of CNV in 
Figure 1
VEGFR-1 ligands suppressed CNV. (A) Stacked 
confocal image of representative laser-induced 
CNV lesions in PBS-treated eyes were larger 
than in VEGF-A–treated (0.29 pmol) or PlGF-1– 
treated (4.3 pmol) eyes and smaller than in 
VEGF-E–treated (0.34 pmol) eyes. Scale bars: 
100 μm. (B) PBS treatment alone did not reduce 
CNV, and VEGF-A (0.1 pmol) reduced CNV 
regardless of the treatment of the fellow eye. 
n = 15–46 per data point. #P < 0.05 compared 
with corresponding uninjected or PBS-treated 
groups. (C) VEGF-A (red; n = 38–46 per data 
point) and PlGF-1 (blue; n = 18 per data point) 
reduced CNV at 1 week after injury in a dose-
dependent fashion. VEGF-E (purple) and PlGF-1 
together (single data point depicted as dotted 
line) suppressed CNV similar to PlGF-1 alone. 
n = 12 per data point. VEGF-E increased 
CNV. n = 12. *P < 0.01, #P < 0.05 compared 
with PBS; §P < 0.01 compared with VEGF-E; 
P > 0.90 compared with PlGF-1. (D) CNV inhib-
ited by CoCl2 (0.77 nmol) was abrogated by 
anti–VEGF-A antibody (6.7 fmol) but not by con-
trol goat IgG (6.7 fmol). Anti–VEGF-A antibody 
modestly reduced CNV compared with goat 
IgG. *P < 0.01 compared with control (PBS). 
#P < 0.05 compared with goat IgG. n = 18–24 
per data point.
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patients with AMD despite widespread disease, that is, thickening 
of the inner aspect of Bruch’s membrane throughout the RPE and 
choroid (N.M. Bressler and W.F. Mieler, personal communication). 
Even when multiple foci exist, typically the ingrowth channels of 
CNV through Bruch membrane are separated by 1 to 2 mm, with 
several intervening fractures in Bruch membrane not containing 
CNV (H.E. Grossniklaus and G.A. Lutty, personal communica-
tion). Interestingly, therapeutic destruction of CNV nearly always 
results in recurrence in the immediate vicinity. We speculated that 
these phenomena result from high levels of VEGF-A emanating 
from the existing focus of CNV and that 
these excessive amounts create a “zone of 
inhibition” that suppresses formation of 
adjacent CNV.
We tested to determine whether a similar 
zone of inhibition exists in the mouse by 
placement of laser spots at 2 different distanc-
es (∼0.75 mm and ∼1.25 mm) from an area of 
preexisting laser injury performed 2 days ear-
lier. The initial injury was placed 2 days ear-
lier because the peak of its VEGF-A response, 
which occurs 3 days after injury (25), would 
occur on the day after the secondary injury, 
a time point when exogenous VEGF-A injec-
tion leads to CNV suppression (Figure 1B). 
CNV volume was significantly decreased in 
the subsequent laser spots, more so in those 
nearer to (53.5% ± 5.7%; P < 0.01) than farther 
from (31.9% ± 10.7%; P = 0.05) the preexist-
ing injury sites (Figure 3, A–C). Neutralizing 
anti–VEGF-A antibody, but not control goat 
IgG, injected on the day interv ening between 
the initial and subsequent laser injuries 
reversed inhibition of CNV; a lower dose (6.7 
fmol) was required to restore normal CNV 
volume in the distant laser spots and a high-
er dose (13.3 fmol) for the spots closer to the preexisting injury 
(Figure 3D). This is consistent with the notion that diffusion of 
VEGF-A from the original injury suppresses CNV in subsequent 
lesions. When laser spots were placed 2 weeks after initial injury, 
there was no significant CNV inhibition (P > 0.34) (Figure 3C), 
consistent with absence of excess VEGF-A at this time point (25). 
These data not only provide a mechanistic basis for the clinical 
observations but also provide insight into why anti–VEGF-A ther-
apies do not maintain the short-term success seen in patients with 
CNV and why they exhibit an inverse dose-response curve (15).
Figure 2
VEGF-A reduced CNV via VEGFR-1. (A) Anti–VEGFR-1 Ab (40 pmol), but not anti–VEGFR-2 
Ab (1.7 pmol), abrogated inhibition of CNV by CoCl2, VEGF-A, and PlGF-1. *P < 0.01 com-
pared with drug alone. Antibody against VEGFR-2 but not VEGFR-1 modestly reduced CNV 
compared with goat IgG (40 pmol). #P < 0.05 compared with goat IgG. n = 10–12 per data 
point. (B) VEGF-A and CoCl2 reduced CNV in wild-type mice but increased it in Vegfr1 tk−/− 
mice compared with PBS-injected fellow eyes. #P < 0.05 compared with PBS. n = 10 per data 
point. CoCl2, 0.77 nmol; VEGF-A, 0.1 pmol; VEGF-E, 0.11 pmol.
Figure 3
Preexisting CNV inhibited subsequent CNV 
via VEGF-A. (A and B) Representative choroi-
dal flat mounts show that CNV lesions (insets 
show magnified images) were smaller in eyes 
(A) where preexisting laser injury (area denot-
ed by arrow) was performed 2 days earlier 
compared with those in eyes (B) without prior 
injury. Arrowheads denote optic nerve. Scale 
bars: 200 μm. (C) Preexisting laser injury cre-
ated 2 days before subsequent injury mark-
edly decreased CNV in the subsequent laser 
spots near (∼0.75 mm) the preexisting injury 
and slightly decreased CNV in spots far (∼1.25 
mm) from it. Preexisting laser injury created 
14 days before subsequent injury in wild-
type mice did not affect CNV of subsequent 
laser spots either near or far from preexisting 
injury. *P < 0.01 compared with eyes without 
preexisting injury; #P < 0.05 compared with far 
lesions in the day 2 group. n = 12 per data 
point. (D) Neutralizing anti–VEGF-A antibody 
reversed this inhibition in a dose-dependent 
manner. #P < 0.05 compared with no injection. 
n = 12 per data point. (C and D).
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VEGF-A ligation of VEGFR-1 negatively regulates VEGFR-2 signaling 
via SHP-1. We studied whether VEGF-A executes its antiangiogenic 
program by directly promoting VEGFR-1 activity or antagonizing 
VEGFR-2 activity. VEGFR-1 tyrosine kinase phosphorylation was 
markedly enhanced following injection of VEGF-A 1 day after laser 
injury (Figure 4A). Simultaneously, we observed increased interac-
tion between the protein tyrosine phosphatase (PTP) Src homology 
domain 2–containing (SH2-containing) tyrosine phosphatase-1 
(SHP-1) and the VEGFR-2 complex as well as a reduction in VEGFR-2 
phosphorylation (Figure 4B). These findings are compatible with a 
model in which VEGFR-1 negatively regulates VEGFR-2 activation via 
SHP-1, although conclusive evidence of a direct effect awaits develop-
ment of a VEGFR-1–specific tyrosine kinase inhibitor. We confirmed 
that VEGFR-2 dephosphorylation translated into a functional inhi-
bition of angiogenesis because the pan-PTP inhibitor bis(maltolato) 
oxovanadium(IV) (BMOV) abrogated VEGF-A–induced inhibition of 
CNV (Figure 4C). Sodium stibogluconate, a potent SHP-1 inhibitor 
(26), also reversed VEGF-A–induced inhibition of CNV (Figure 4C). 
Further, we demonstrated that Shp1–/– mice were resistant to VEGF-A– 
induced CNV suppression (Figure 4D). Collectively, these data con-
firm a specific effect of VEGF-A on SHP-1. We also observed that 
VEGF-A did not modulate the interaction between VEGFR-2 and 
other PTPs, such as PTP1B and human low molecular weight cytoplas-
mic PTP (HCPTPA) (data not shown). These data demonstrate that, 
after laser injury, excess VEGF-A negatively regulates VEGFR-2 sig-
naling and identify a potentially novel mechanism by which VEGF-A 
can modulate its own angiogenic action.
SPARC regulates VEGF-A-induced effects on CNV. In contrast to their 
antiangiogenic action when injected after laser injury, VEGF-A 
and CoCl2 increased CNV when injected 1 day before injury (Fig-
ure 5). This was mediated via VEGFR-2 signaling because VEGF-E, 
but not PlGF-1, promoted CNV when injected 1 day before injury 
(Figure 5). In most tissues, VEGFR-1 autophosphorylation was 
weak, possibly because it is constitutively repressed. Therefore, we 
postulated the presence of a protein that would restrain VEGFR-1 
kinase at rest and would itself be diminished after injury, thereby 
relieving the functional block of VEGFR-1 activation.
One such candidate is SPARC, which we previously demonstrat-
ed binds to VEGF-A and inhibits the kinase activity of VEGFR-1 
but not VEGFR-2 in vitro (17). SPARC was constitutively expressed 
in the RPE/choroid, but its expression declined after injury and 
recovered to near-baseline levels 2 days later (Figure 6A). We also 
identified a specific binding interaction between SPARC and 
VEGF-A in the mouse eye in vivo (Figure 6B); this interaction was 
specific because VEGF-A was not bound to IGF-binding protein-3 
(IGFBP-3), a matricellular protein like SPARC (Figure 6C). Sup-
pression of CNV induced by VEGF-A injected 1 day after injury, 
when levels of SPARC were declining, was dose dependently abol-
ished by recombinant human SPARC (2.5–7.5 pmol), which is 
92% identical to mouse SPARC (Figure 6D) (27). Restoration of 
CNV by exogenous SPARC was essentially eliminated by a neutral-
izing antibody against SPARC, confirming the specificity of this 
response (Figure 6D). The anti-SPARC IgG (26.7–80 pmol) inhib-
ited the augmented CNV resulting from VEGF-A injected 1 day 
before injury, when SPARC levels were high (Figure 6E).
Figure 4
VEGF-A decreased CNV through VEGFR-1–induced 
negative transduction of VEGFR-2 via SHP-1. (A) 
Representative figure shows VEGFR-1 phosphoryla-
tion levels in RPE/choroid of eyes before injury (con-
trol) and 30 minutes after intravitreous injection of PBS 
or VEGF-A, 1 day after injury. n = 5. WB, Western 
blot. (B) Representative figure shows that VEGF-A, 
injected 1 day after laser injury, increased interac-
tion of SHP-1 with VEGFR-2 and reduced VEGFR-2 
phosphorylation at 30 minutes after injection, 1 day 
after injury, and before injury (control), without affect-
ing VEGFR-2 expression. Densitometric ratios of 
SHP-1 to total VEGFR-2 and of phosphorylated (P) 
to total (T) VEGFR-1 or VEGFR-2 are shown before 
(control) and after injury. Ratios were normalized to 
control values. n = 5. (C) VEGF-A–induced CNV sup-
pression was abrogated by BMOV (0.16 μmol) and 
sodium stibogluconate (SSG) (0.56 nmol) in wild-type 
mice. n = 12 per data point. (D) VEGF-A did not sig-
nificantly suppress CNV in Shp1–/– mice (n = 12 per 
data point; P = 0.44). *P < 0.05 compared with PBS. 
VEGF-A, 0.1 pmol.
Figure 5
VEGF-A increased CNV before injury via VEGFR-2. Injected 1 day 
before injury, VEGF-A (0.1 pmol), VEGF-E (0.11 pmol), and CoCl2 
(0.77 nmol), but not PlGF-1 (43.1 pmol), increased CNV. *P < 0.05 
compared with PBS. n = 10 per data point.
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The pro- and antiangiogenic actions of VEGF-A injected before 
versus after injury, respectively, were duplicated in Sparc+/+ mice. 
However, in Sparc–/– mice, the proangiogenic response of VEGF-A 
injected 1 day before injury was eliminated, whereas the antiangio-
genic response of VEGF-A injected 1 day after injury was preserved 
(Figure 6F). Of note, the basal CNV response in Sparc–/– eyes was 
modestly but significantly greater than in Sparc+/+ eyes, consistent 
with the diminished ECM characteristic of Sparc–/– mice that has 
been proposed as permissive for enhanced tumor growth (28). 
The modest difference between Sparc+/+ mice and C57BL/6J mice 
in basal CNV response is attributed to the genetic variation aris-
ing from their mixed background. Collectively, these data indicate 
that SPARC limits the capacity of excess VEGF-A to suppress CNV 
via VEGFR-1 and that the transient decline of SPARC in the wake 
of injury unmasks the antiangiogenic action of VEGF-A due to 
unsilencing of VEGFR-1 activation.
Discussion
Historically, VEGFR-1 was assigned a role as a nonsignaling decoy 
receptor because of the low activity and embryonic dispensability 
of its tyrosine kinase function. More recently, its role has become 
more interesting because VEGFR-1 signaling has been reported 
both to promote (6, 7) and suppress (8) VEGF-A–driven angiogen-
esis. We report not only that PlGF-1 inhibits inflammatory CNV, 
extending the scope of VEGFR-1 function, but also what we believe 
is the unprecedented observation that VEGF-A itself can suppress 
angiogenesis. Multiple lines of evidence emerging from genetic 
ablation, antibody neutralization, and receptor-selective ligand 
activation all strongly support the thesis that the antiangiogenic 
action of VEGF-A is mediated by VEGFR-1. Previously, VEGF-A 
has been reported to reduce VEGF-E–induced VEGFR-2 tyrosine 
kinase phosphorylation in capillary endothelial cells in vitro, rais-
ing the provocative hypothesis that VEGF-A could limit its own 
angiogenic activity through VEGFR-1 (29). We have presented in 
vivo confirmation of this hypothesis. These findings contribute 
significantly to our understanding of the consequences of the 
interaction of VEGFR-1 with its ligands and describe a unique 
mechanism by which VEGFR-1 regulates angiogenesis.
Prior reports have noted that the biological effects of VEGF-A are 
dose dependent. These observations are consistent with our data, 
which indicate that high levels of VEGF-A cannot sustain, and 
indeed may inhibit, CNV. Exogenous VEGF-A in the myocardium 
or skeletal muscle can lead to dysregulated vasculogenesis (30, 31) 
and disrupt embryonic intersomitic artery formation (32). In addi-
tion, exogenous VEGF-A can inhibit smooth muscle cell prolifera-
tion, without affecting angiogenesis (33, 34). However, we believe 
our data are the first to demonstrate direct arrest of endothelial cell 
proliferation and frank inhibition of angiogenesis by VEGF-A.
These data do not contradict the well-described angiogenic prop-
erties of VEGF-A. Indeed, our data indicating that intravitreous 
injection of antibodies against VEGF-A or VEGFR-2 reduces laser-
induced CNV confirm findings of other investigators using differ-
ent antagonists (11, 23). Rather, they unveil an unrecognized ability 
of excess VEGF-A in the postinjury setting to suppress angiogenesis 
by predominantly activating VEGFR-1 signaling and preventing 
endothelial cells from responding to mitogenic signals. It appears 
that the system is exquisitely sensitive to the precise level of VEGF-A 
in the immediate postinjury period and responds differently if that 
level exceeds the concentration of VEGF-A induced by injury. The 
“switch” that diverts the injured tissue away from proliferation is 
driven through VEGFR-1 signaling, which appears to be dominant 
in an environment of excess VEGF-A, in contrast to the usual domi-
nance of VEGFR-2. Unraveling this antagonistic pathway of excess 
VEGF-A and comparing it with those of existing angiogenic inhibi-
tors may reveal additional robust and powerful therapeutic targets 
in the panoply of angiogenesis-driven disorders.
Figure 6
SPARC regulated VEGF-A effects on CNV. (A) Constitutive (control) RPE/choroid expression of SPARC was decreased 1 day after laser injury 
and recovered 2 days after injury. Figure is representative of 3 experiments. (B and C) Immunoprecipitation of 3 independent samples revealed 
that VEGF-A interacted with SPARC (B) but not IGF binding protein-3 (IGFBP-3) (C) in vivo. (D) CNV inhibition by VEGF-A injected 1 day after 
injury was abolished by recombinant human SPARC (rhSPARC) and restored by neutralizing anti-SPARC Ab (80 pmol). *P < 0.05 compared with 
PBS. Recombinant SPARC injection alone (white bar) did not change CNV compared with PBS. (E) Neutralizing anti-SPARC Ab (26.7 pmol) but 
not control mouse IgG abrogated CNV increase induced by VEGF-A 1 day before injury. *P < 0.05 compared with PBS. (F) VEGF-A injected 1 
day before laser injury increased CNV in SPARC+/+ mice but not in SPARC–/– mice. VEGF-A injected 1 day after laser injury decreased CNV in 
SPARC+/+ and SPARC–/– mice. *P < 0.05 compared with PBS injection on the same day. VEGF-A, 0.1 pmol. n = 10–14 per data point (D–F).
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Rakic and colleagues demonstrated that systemic administration 
of anti–VEGFR-1 antibody inhibits experimental CNV (24), while 
we found that intravitreous delivery did not. This divergence could 
arise from the fact that cell populations are affected differentially by 
local versus systemic VEGFR-1 blockade. Systemic but not intravit-
reous VEGFR-1 blockade would interfere with mobilization of bone 
marrow–derived progenitor cells (35) that are known to contribute 
to CNV (36, 37). This difference is clinically relevant as most anti–
VEGF-A therapies for CNV rely on intravitreous delivery to mini-
mize potential adverse effects of systemic VEGF-A antagonism.
Rakic et al. (24) also demonstrated that laser-induced CNV is 
inhibited in Plg f –/– mice, which is consistent with the role of PlGF 
in the bone marrow, where it mobilizes progenitors either direct-
ly by recruiting VEGFR-1+ cells or indirectly by inducing matrix 
metalloproteinase-9, which increases progenitor cell proliferation 
and motility via release of soluble Kit ligand (35). In contrast, intra-
vitreous injection of PlGF, which inhibits CNV when administered 
after injury, would not execute such effects on the bone marrow. 
These differences also might have emerged because exogenous and 
endogenous PlGF may heterodimerize with VEGF-A differently in 
CNV. The role of these heterodimers is controversial because they 
have been reported both to promote (38) and antagonize (39) neo-
vascularization. An analogous variation is observed in experimen-
tal retinal neovascularization, which is inhibited both by genetic 
ablation of Plgf (6) and by intravitreous administration of PlGF 
(40), although the latter may be due to increased cell survival. A 
similar divergence in angiogenic response to endogenous and 
exogenous proteins exists in the case of other cytokines, such as 
plasminogen activator inhibitor type I (PAI-1). Indeed, Rakic and 
colleagues also have shown that laser-induced CNV is inhibited 
both in Pai–/– mice and in PAI-1–treated wild-type mice (41). The 
apparently different effects of endogenous and exogenous PlGF 
also might reflect modulation of plasminogen activator activity 
by VEGFR-1 activation (42, 43).
Reduction in CNV in Plgf –/– mice also is intriguing because these 
mice express other VEGFR-1 ligands, including VEGF-A (6). This 
raises the formal possibility that reduced CNV in Plgf –/– mice might 
reflect molecular or developmental plasticity in response to gene 
disruption rather than PlGF deficiency alone. Secondary develop-
mental effects induced by the altered vascular phenotype account 
for a similar divergence phenomenon in Alk1–/– mice, which display 
enhanced angiogenesis (44), while enforced activin receptor–like 
kinase 1 (ALK1) expression stimulates endothelial cell migration 
and proliferation (45). It also is possible that subtle defects in ocu-
lar vascular development in Plg f –/– mice reported by Carmeliet and 
colleagues (6) might have influenced their CNV responses.
These data add VEGF-A to the group of cytokines, such as 
angiopoietin-1 (46–48), nitric oxide (49, 50), pigment epithelium– 
derived factor (51–53), and TGF-β (45, 54), whose modulation 
of angiogenesis displays context-dependent bidirectionality. The 
paradoxical effect of VEGF-A resembles that of TGF-β, which is 
proangiogenic at low doses and antiangiogenic at high doses, an 
effect attributed to differential activation of the TGF-β receptors 
ALK1 and ALK5 (45), akin to the differential routing via VEGFR-1 
and VEGFR-2. This Janus-like effect reveals novel therapeutic strat-
egies to modulate angiogenesis in the setting of inflammation and 
highlights the importance of developing assays for markers such 
as SPARC to target therapeutics more specifically.
In most systems, VEGFR-1 tyrosine kinase activity has been 
described as weak. Our findings provide a paradigm by which 
its activation is controlled in vivo by SPARC and illustrate the 
multifunctional nature of this receptor in promoting or curtail-
ing angiogenesis. These data might also explain the divergent 
outcomes of experiments involving VEGFR-1 function in dif-
ferent angiogenesis models. The poor intrinsic kinase activity of 
VEGFR-1 in many systems may be due to repressive elements in 
its juxtamembrane domain (55). It is also possible that VEGFR-1 
signaling could occur without phosphorylation of consensus-pos-
itive regulatory tyrosine residues, i.e., VEGFR-1 could be a poor 
substrate for itself. Further investigation of the role of SPARC in 
maintaining repression of VEGFR-1 may improve our fragmentary 
understanding of its activation, particularly during development 
and in cancer, where this receptor appears functional. In addition, 
the propensity of the macula to develop CNV despite widespread 
subretinal disease in AMD may be related to the concentration of 
SPARC in this central region in monkeys (56) (and presumably 
in humans), which may prevent downregulation of proangiogenic 
VEGFR-2 signaling by VEGFR-1.
The expression and activity of SPARC are segregated largely to 
tissues that are undergoing remodeling or turnover. As such, it is 
well placed to regulate the activity of potent growth factors such as 
VEGF-A, which often are the primary stimuli for remodeling of the 
local microenvironment. The present study provides a physiologi-
cal example of how SPARC potentially regulates the angiogenic 
process. The initiation of angiogenesis by soluble factors such 
as VEGF-A is complex and involves the activation of individual 
endothelial cells that express both VEGFR-1 and VEGFR-2. Our 
data point to extracellular adaptor proteins as critical linchpins in 
the induction of the VEGFR-2–driven angiogenic program. Previ-
ous studies (17) showed that SPARC can interfere with VEGF-A 
ligation of VEGFR-1 and that SPARC-mediated inhibition of 
VEGF-A–induced phosphorylation of VEGFR-1 was long lived (at 
least 24 hours). In the context of CNV, this time frame is relevant 
to the demonstrated activity of VEGF-A in that setting. Investi-
gations using mice with a deficiency in a matricellular protein 
(e.g., thrombospondin-1 and/or -2, the SPARC ortholog hevin, or 
SPARC) support the hypothesis that the function of matricellu-
lar proteins is contextual and that regulated expression of these 
proteins is important for maintenance of tissue homeostasis and 
responses to injury (16, 57, 58).
The basal CNV response of Sparc–/– mice was greater than that 
of wild-type counterparts (Figure 6D), a result consistent with the 
heightened neovascular response in sponge implants reported in 
Sparc–/– animals as well as the synergistic increase in vascularization 
in the foreign body response of SPARC/hevin double-null mice 
(59, 60). The inhibitory effect of SPARC on vessel growth resides in 
part in the C terminal, Ca+2-binding EF hand, whereas other pep-
tides released by plasmin or stromelysin-1 stimulate angiogenesis 
by affecting the cell cycle and/or migration of endothelial cells (27, 
61). Our present study emphasizes the contextual dependence of 
SPARC and its activity as a regulator of angiogenesis.
Our data define a previously unrecognized autoregulatory poten-
tial of excess VEGF-A and are relevant to ongoing clinical trials exam-
ining anti–VEGF-A therapy in AMD and VEGF-A over-expression in 
ischemic limb and cardiac disease. Data from the pegaptanib clini-
cal trials in patients with AMD showed an inverse therapeutic dose 
response (15), indicating that partial inhibition of VEGF-A could be 
optimal. The inability of this drug to arrest the increasing size of the 
CNV lesion with time in patients with AMD indicates that VEGF-A 
might have dual actions in the human eye as well. However, that 
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pegaptanib decreased the rate of vascular leakage points to a diver-
gent response of VEGF-A in mediating growth versus hyperperme-
ability of new blood vessels. Whether similar bifurcation of VEGF-A 
signaling occurs in laser-induced CNV warrants investigation.
Our findings provide insight into the context and stage depen-
dency of the role of VEGF-A in ocular neovascularization as well as 
interactions between a matricellular protein and a VEGF receptor 
that regulate and route signaling by VEGF-A. Our findings also 
demonstrate alternative pathways of VEGF-A signal transduction 
and emphasize the need to clarify the complex effects of interac-
tions among VEGF-A, its receptors, SPARC, and the chemokine 
network in ocular neovascularization before VEGF-A alone can be 
considered an ideal therapeutic target.
Methods
Animals. Wild-type C57BL/6 mice were purchased from Jackson Labora-
tory. Vegfr-1 tk–/– mice were generated as described previously (5) and back-
crossed 6–10 times to C57BL/6 animals. Sparc–/– and Sparc+/+ mice on a 
mixed C57BL/6 × 129/SvJ background have been described (62). Mice 
(6- to 8-week-old males) were anesthetized by intraperitoneal injection of 
ketamine (50 mg/kg; Fort Dodge Animal Health) and xylazine (10 mg/kg; 
Phoenix Scientific Inc.), and pupils were dilated with topical tropicamide 
(1%; Alcon). Experiments were approved by the University of Kentucky 
Institutional Animal Care and Use Committee.
CNV.	Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 μm) (Ocu-
Light GL; IRIDEX Corp.) was performed on both eyes (3 spots per eye) 
of each animal to induce CNV as described (25, 63). CNV volumes were 
measured by scanning laser confocal microscope (TCS SP; Leica) as report-
ed (25, 63), with 0.5% FITC-conjugated Griffonia simplicifolia isolectin B4 
(Vector Laboratories) or 0.5% FITC-conjugated rat anti-mouse CD31 (BD 
Biosciences), or by cardiac perfusion with 5 mg/ml FITC-dextran (2 × 106 
average weight; Sigma-Aldrich). Pairwise comparisons among volumes 
obtained by lectin, CD31, and dextran staining were highly correlated 
(r2 > 0.90). CNV volumes per laser lesion were compared by hierarchical 
logistic regression using repeated measures analysis as described (25, 63). 
Results are expressed as mean ± SEM (n refers to number of animals). Type I 
error not exceeding 0.05 was deemed significant.
Drug treatments. VEGF-A164 (0.02–0.95 pmol), PlGF-1 (0.03–43.1 pmol), 
neutralizing goat antibodies against (a) mouse VEGF-A (6.7–13.3 fmol), 
(b) mouse VEGFR-1 (6.7–40 pmol), (c) mouse VEGFR-2 (0.17–1.7 pmol; 
all R&D Systems); CoCl2 (0.77 nmol; Sigma-Aldrich), recombinant human 
SPARC (64) (2.5–7.5 pmol), neutralizing mouse antibody against human 
SPARC (65) (clone 293; 26.7–80 pmol; cross-reactive with mouse SPARC), 
VEGF-E (0.11–1.14 pmol; Cell Sciences), BMOV (0.16 μmol; gift of J.H. 
McNeill and C. Orvig, University of British Columbia, Vancouver, Canada), 
or sodium stibogluconate (SSG) (0.56 nmol) were dissolved in PBS (Sigma-
Aldrich), and injected into the vitreous cavity in a total volume of 1 μl with 
a 33-gauge Exmire microsyringe (Ito Corp.).
Western blotting. Equal amounts of total protein from RPE/choroid were 
resolved on SDS 4–20% polyacrylamide gradient gels and transferred to 
nitrocellulose membranes for Western blotting with goat antibody against 
mouse SPARC (1:500; R&D Systems). Loading was assessed by blotting 
with rabbit antibody against human GAPDH (1:2,000; Abcam).
Immunoprecipitation and immunoblotting. RPE/choroid lysates were 
immunoprecipitated with goat antibodies against mouse VEGFR-1 or 
VEGFR-2 (8 μg/ml; R&D Systems) that were immobilized on protein 
G-agarose, subjected to SDS-PAGE, immunoblotted with mouse mono-
clonal antibody against phosphotyrosine (1:1,000; Upstate USA Inc.), and 
subsequently reprobed with rabbit antibodies against human VEGFR-1 or 
mouse VEGFR-2 (1:500; Santa Cruz Biotechnology Inc.). SPARC–VEGF-A 
 interaction was identified by immunoprecipitation with mouse anti-
body against human VEGF-A (66) (clone 12D7; 4 μg/ml; cross-reactive 
with mouse VEGF-A) and immunoblotting with mouse antibody against 
human SPARC (clone 293; 0.75 μg/ml) or with goat antibody against 
mouse IGFBP-3 (0.1 μg/ml; R&D Systems)
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